Alex DeSeabra

BioFactura, Inc. develops and manufactures high-value biosimilars, biodefense medical countermeasures, and client-selected novel drugs. It also specializes in developing and performing in-process and release analytical assays including HPLC methods, SDS-PAGE and Western analysis, antibody/antigen capture ELISAs, and bioactivity methods. The company was founded by Darryl Sampey and Alexandre DeSeabra in 2004 and is headquartered in Frederick, MD.

BioFactura, Inc. develops and manufactures high-value biosimilars, biodefense medical countermeasures, and client-selected novel drugs. It also specializes in developing and performing in-process and release analytical assays including HPLC methods, SDS-PAGE and Western analysis, antibody/antigen capture ELISAs, and bioactivity methods. The company was founded by Darryl Sampey and Alexandre DeSeabra in 2004 and is headquartered in Frederick, MD.

BioFactura, Inc. develops and manufactures high-value biosimilars, biodefense medical countermeasures, and client-selected novel drugs. It also specializes in developing and performing in-process and release analytical assays including HPLC methods, SDS-PAGE and Western analysis, antibody/antigen capture ELISAs, and bioactivity methods. The company was founded by Darryl Sampey and Alexandre DeSeabra in 2004 and is headquartered in Frederick, MD.